Zacks Investment Research cut shares of The Joint (NASDAQ:JYNT) from a buy rating to a hold rating in a research note published on Friday.

According to Zacks, “The Joint Corp. is a healthcare franchisor of chiropractic clinics. The Company’s plans include: Single Visit, Premium Wellness Plan and Wellness Plan. It also provides a family wellness plan. The Company also provides removal of subluxations. It operates its clinics across: Albany, New York; Austin, Texas; Brentwood, California; Fort Mill, South Carolina; Lubbock, Texas; Lynnwood, Washington; Middletown, New Jersey; San Antonio, Texas; San Diego, California and Spartanburg, South Carolina, among others. The Joint Corp. is headquartered in Scottsdale, Arizona. “

How to Become a New Pot Stock Millionaire

Other analysts also recently issued research reports about the stock. Lake Street Capital began coverage on shares of The Joint in a research note on Wednesday, March 28th. They issued a buy rating for the company. Maxim Group reissued a buy rating and issued a $7.00 price objective on shares of The Joint in a research note on Friday, March 9th. Finally, ValuEngine raised shares of The Joint from a sell rating to a hold rating in a research note on Sunday, December 31st. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The Joint has a consensus rating of Buy and a consensus target price of $7.05.

Shares of NASDAQ JYNT opened at $7.04 on Friday. The company has a current ratio of 1.34, a quick ratio of 1.34 and a debt-to-equity ratio of 0.20. The Joint has a 1 year low of $3.41 and a 1 year high of $7.25.

The Joint (NASDAQ:JYNT) last announced its quarterly earnings data on Thursday, March 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.03) by $0.01. The business had revenue of $6.93 million during the quarter, compared to the consensus estimate of $6.48 million. The Joint had a negative net margin of 13.01% and a negative return on equity of 66.74%. research analysts anticipate that The Joint will post 0.08 EPS for the current fiscal year.

Institutional investors have recently bought and sold shares of the company. Skylands Capital LLC raised its stake in shares of The Joint by 11.0% during the fourth quarter. Skylands Capital LLC now owns 612,529 shares of the company’s stock valued at $3,038,000 after acquiring an additional 60,900 shares in the last quarter. Russell Investments Group Ltd. raised its stake in shares of The Joint by 28.4% during the third quarter. Russell Investments Group Ltd. now owns 112,900 shares of the company’s stock valued at $538,000 after acquiring an additional 25,000 shares in the last quarter. Deutsche Bank AG raised its stake in shares of The Joint by 3,839.1% during the fourth quarter. Deutsche Bank AG now owns 59,087 shares of the company’s stock valued at $293,000 after acquiring an additional 57,587 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new stake in shares of The Joint during the fourth quarter valued at approximately $379,000. 49.57% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This article was originally published by Daily Political and is the property of of Daily Political. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://www.dailypolitical.com/2018/04/16/the-joint-jynt-stock-rating-lowered-by-zacks-investment-research.html.

About The Joint

The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics in the United States. It operates through direct ownership, management arrangements, franchising, and the sale of regional developer rights. As of December 31, 2017, the company operated 352 franchised clinics and 47 company-owned or managed clinics.

Get a free copy of the Zacks research report on The Joint (JYNT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for The Joint Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Joint and related companies with MarketBeat.com's FREE daily email newsletter.